CRISPR/Cas9 gene editing: From basic mechanisms to improved strategies for enhanced genome engineering in vivo

Jayme Salsman; Jean Yves Masson; Alexandre Orthwein; Graham Dellaire

doi:10.2174/1566523217666171122094629

CRISPR/Cas9 gene editing: From basic mechanisms to improved strategies for enhanced genome engineering in vivo

Jayme Salsman, Jean Yves Masson, Alexandre Orthwein, Graham Dellaire

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

Introduction: Targeted genome editing using the CRISPR/Cas9 technology is becoming a major area of research due to its high potential for the treatment of genetic diseases. Our understanding of this approach has expanded in recent years yet several new challenges have presented themselves as we explore the boundaries of this exciting new technology. Chief among these is improving the efficiency but also the preciseness of genome editing. The efficacy of CRISPR/Cas9 technology relies in part on the use of one of the major DNA repair pathways, Homologous recombination (HR), which is primarily active in S and G2 phases of the cell cycle. Problematically, the HR potential is highly variable from cell type to cell type and most of the cells of interest to be targeted in vivo for precise genome editing are in a quiescent state. Conclusion: In this review, we discuss the recent advancements in improving targeted CRISPR/Cas9 based genome editing and the promising ways of delivering this technology in vivo to the cells of interest.

Original language	English
Pages (from-to)	263-274
Number of pages	12
Journal	Current Gene Therapy
Volume	17
Issue number	4
DOIs	https://doi.org/10.2174/1566523217666171122094629
Publication status	Published - 2017

Bibliographical note

Funding Information:
This work was supported in part by research grants from the Canadian Institutes of Health Research (CIHR) to GD (MOP-84260), AO (PJ/361708 and PJ/376245), and JYM (PJ/375408), the Natural Sciences and Engineering Research Council of Canada (NSERC) to GD (RGPIN/05616), the Cole Foundation and the Sir Mortimer B. Davis Foundation from the Jewish General Hospital for AO. GD is a Senior Scientist of the Beatrice Hunter Cancer Research Institute (BHCRI) and this work was also supported in part by a Bridge grant from BHCRI to GD. J.S. was a recipient of a BHCRI postdoctoral fellowship made possible by the Harvey Graham Cancer Research Fund as part of the Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR. AO is a Canada Research Chair Tier 2 in Genome Stability and Haematological malignancies.

Publisher Copyright:
© 2017 Bentham Science Publishers.

ASJC Scopus Subject Areas

Molecular Medicine
Molecular Biology
Genetics
Drug Discovery
Genetics(clinical)

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Review

Access to Document

10.2174/1566523217666171122094629

Cite this

@article{0194784f65fe42178d92db2f2c7afea1,

title = "CRISPR/Cas9 gene editing: From basic mechanisms to improved strategies for enhanced genome engineering in vivo",

abstract = "Introduction: Targeted genome editing using the CRISPR/Cas9 technology is becoming a major area of research due to its high potential for the treatment of genetic diseases. Our understanding of this approach has expanded in recent years yet several new challenges have presented themselves as we explore the boundaries of this exciting new technology. Chief among these is improving the efficiency but also the preciseness of genome editing. The efficacy of CRISPR/Cas9 technology relies in part on the use of one of the major DNA repair pathways, Homologous recombination (HR), which is primarily active in S and G2 phases of the cell cycle. Problematically, the HR potential is highly variable from cell type to cell type and most of the cells of interest to be targeted in vivo for precise genome editing are in a quiescent state. Conclusion: In this review, we discuss the recent advancements in improving targeted CRISPR/Cas9 based genome editing and the promising ways of delivering this technology in vivo to the cells of interest.",

author = "Jayme Salsman and Masson, {Jean Yves} and Alexandre Orthwein and Graham Dellaire",

note = "Funding Information: This work was supported in part by research grants from the Canadian Institutes of Health Research (CIHR) to GD (MOP-84260), AO (PJ/361708 and PJ/376245), and JYM (PJ/375408), the Natural Sciences and Engineering Research Council of Canada (NSERC) to GD (RGPIN/05616), the Cole Foundation and the Sir Mortimer B. Davis Foundation from the Jewish General Hospital for AO. GD is a Senior Scientist of the Beatrice Hunter Cancer Research Institute (BHCRI) and this work was also supported in part by a Bridge grant from BHCRI to GD. J.S. was a recipient of a BHCRI postdoctoral fellowship made possible by the Harvey Graham Cancer Research Fund as part of the Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR. AO is a Canada Research Chair Tier 2 in Genome Stability and Haematological malignancies. Publisher Copyright: {\textcopyright} 2017 Bentham Science Publishers.",

year = "2017",

doi = "10.2174/1566523217666171122094629",

language = "English",

volume = "17",

pages = "263--274",

journal = "Current Gene Therapy",

issn = "1566-5232",

publisher = "Bentham Science Publishers B.V.",

number = "4",

}

TY - JOUR

T1 - CRISPR/Cas9 gene editing

T2 - From basic mechanisms to improved strategies for enhanced genome engineering in vivo

AU - Salsman, Jayme

AU - Masson, Jean Yves

AU - Orthwein, Alexandre

AU - Dellaire, Graham

N1 - Funding Information: This work was supported in part by research grants from the Canadian Institutes of Health Research (CIHR) to GD (MOP-84260), AO (PJ/361708 and PJ/376245), and JYM (PJ/375408), the Natural Sciences and Engineering Research Council of Canada (NSERC) to GD (RGPIN/05616), the Cole Foundation and the Sir Mortimer B. Davis Foundation from the Jewish General Hospital for AO. GD is a Senior Scientist of the Beatrice Hunter Cancer Research Institute (BHCRI) and this work was also supported in part by a Bridge grant from BHCRI to GD. J.S. was a recipient of a BHCRI postdoctoral fellowship made possible by the Harvey Graham Cancer Research Fund as part of the Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR. AO is a Canada Research Chair Tier 2 in Genome Stability and Haematological malignancies. Publisher Copyright: © 2017 Bentham Science Publishers.

PY - 2017

Y1 - 2017

N2 - Introduction: Targeted genome editing using the CRISPR/Cas9 technology is becoming a major area of research due to its high potential for the treatment of genetic diseases. Our understanding of this approach has expanded in recent years yet several new challenges have presented themselves as we explore the boundaries of this exciting new technology. Chief among these is improving the efficiency but also the preciseness of genome editing. The efficacy of CRISPR/Cas9 technology relies in part on the use of one of the major DNA repair pathways, Homologous recombination (HR), which is primarily active in S and G2 phases of the cell cycle. Problematically, the HR potential is highly variable from cell type to cell type and most of the cells of interest to be targeted in vivo for precise genome editing are in a quiescent state. Conclusion: In this review, we discuss the recent advancements in improving targeted CRISPR/Cas9 based genome editing and the promising ways of delivering this technology in vivo to the cells of interest.

AB - Introduction: Targeted genome editing using the CRISPR/Cas9 technology is becoming a major area of research due to its high potential for the treatment of genetic diseases. Our understanding of this approach has expanded in recent years yet several new challenges have presented themselves as we explore the boundaries of this exciting new technology. Chief among these is improving the efficiency but also the preciseness of genome editing. The efficacy of CRISPR/Cas9 technology relies in part on the use of one of the major DNA repair pathways, Homologous recombination (HR), which is primarily active in S and G2 phases of the cell cycle. Problematically, the HR potential is highly variable from cell type to cell type and most of the cells of interest to be targeted in vivo for precise genome editing are in a quiescent state. Conclusion: In this review, we discuss the recent advancements in improving targeted CRISPR/Cas9 based genome editing and the promising ways of delivering this technology in vivo to the cells of interest.

UR - http://www.scopus.com/inward/record.url?scp=85041379872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041379872&partnerID=8YFLogxK

U2 - 10.2174/1566523217666171122094629

DO - 10.2174/1566523217666171122094629

M3 - Review article

C2 - 29173169

AN - SCOPUS:85041379872

SN - 1566-5232

VL - 17

SP - 263

EP - 274

JO - Current Gene Therapy

JF - Current Gene Therapy

IS - 4

ER -

CRISPR/Cas9 gene editing: From basic mechanisms to improved strategies for enhanced genome engineering in vivo

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this